Jason Haldas

Yale University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Jonathan S. Leventhal

Yale University

Scott Gettinger

Yale Cancer Center

Wei Wang

The University of Texas MD Anderson Cancer Center

Ashita D. Talsania

Yale University

Gauri Panse

Yale University

Emily Coleman

Tulane University

Annika Belzer

Yale University

John Lazarchick

University of South Alabama

Michael O. Nguyen

University of California, Irvine

Janellen Smith

University of California, Irvine

Cooperative Institutions

Yale University

Yale New Haven Hospital

Smilow Cancer Hospital

The University of Texas MD Anderson Cancer Center

University of California, San Francisco

University of California, Irvine

Yale Cancer Center

University of New Haven

Moffitt Cancer Center

Bristol-Myers Squibb (Germany)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Post-transplant Lymphoproliferative Disorders: T-cell Lymphoma Following Cardiac Transplant

Leukemia & lymphoma/Leukemia and lymphoma (2002)

Jason Haldas Wei Wang John Lazarchick

AbstractPost-transplant lymphoproliferative disorders (PTLD) are a frequently fatal complication occurring after transplant. The majority of cases are of B-cell origin but a smaller percentage of cases are of T-cell origin. The etiology of these disorders is unclear, however, EBV (Epstein-Barr virus) in the context of immunosupperssion is thought to play a role, particularly in B-cell PTLD. We report a case of T-cell PTLD limited to the bone marrow occurring eight years post-cardiac transplantation and review the literature on T-cell PTLD after heart transplant.KeywordsPtldHeart TransplantationT-cell LymphomaImmunosuppressionEpstein-Barr Virus

Lymphoproliferative Disorders

Etiology

Post-transplant lymphoproliferative disorder

Bone marrow transplant

10.1080/10428190290006332

Cite

Citations (20)

Pityriasis rubra pilaris–like erythroderma in the setting of pembrolizumab therapy responsive to acitretin

JAAD Case Reports (2018)

Emily Coleman Gauri Panse Jason Haldas Scott Gettinger Jonathan S. Leventhal

Numerous cutaneous adverse effects have been associated with programmed death 1 (PD-1) inhibitors including maculopapular eruptions, pruritus, eczema, lichenoid reactions, leukoderma, psoriasis, sarcoidosis, immunobullous disorders, and Stevens-Johnson syndrome.1,2 Here we report the first case, to our knowledge, of pityriasis rubra pilaris (PRP)-like erythroderma in the setting of anti–PD-1 therapy responsive to acitretin and topical steroids.

Pityriasis rubra pilaris

Acitretin

Erythroderma

Toxic Epidermal Necrolysis

10.1016/j.jdcr.2018.06.022

Cite

Citations (19)

Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use

JAMA Dermatology (2022)

Annika Belzer Michael O. Nguyen Ashita D. Talsania Jason Haldas Janellen Smith

This case series describes the different dermatologic adverse events that patients experienced while using amivantamab.

10.1001/jamadermatol.2022.4466

Cite

Citations (8)